正在加載......
Research and development of NTU 568
│
Research Team
│
Introduction of NTU 568
│
Research Achievement
│
Patent
X
會員帳號 :
會員密碼 :
忘記密碼
加入會員
Reduces insulin resistance and blood sugar
總共 11 筆 當前 1 - 10
HOME
>
Research Achievement
>
Publication of monascin and ankaflavin
>
Reduces insulin resistance and blood sugar
A Novel PPARgamma Agonist Monascin's Potential Application in Diabetes Prevention
Treatment of Metabolic Syndrome with Ankaflavin, a Secondary Metabolite Isolated from the Edible Fungus Monascus spp
Monacolin K and Monascin Attenuated Pancreas Impairment and Hyperglycemia Induced by Advanced Glycation Endproducts in BALC/c Mice
A Novel Natural Nrf2 Activator with PPARg-Agonist (Monascin) Attenuates the Toxicity of Methylglyoxal and Hyperglycemia
Monascin and AITC Attenuate Methylglyoxal-Induced PPARg Phosphorylation and Degradation through Inhibition of the Oxidative Stress/PKC Pathway Depending on Nrf2 Activation
Monascin Improves Diabetes and Dyslipidmia by Regulation PPARg and Inhibiting Lipogenesis in Fructose-Rich Diet-Induced C57BL/6 Mice
Effects of Monascin on Anti-inflammation Mediated by Nrf2 Activation in Advanced Glycation End Product-Treated THP-1 Monocytes and Methylglyoxal-Treated Wistar Rats
Ankaflavin Regulates Adipocyte Function and Attenuates Hyperglycemia Caused by High-Fat Diet via PPAR-g Activation
Ankaflavin: a Natural Novel PPARg Agonist Upregulates Nrf2 to Attenuate Methylglyoxal-Induce Diabetes in vivo
Monascin from Red Mold Dioscorea as a Novel Antidiabetic and Antioxidative Stress Agent in Rats and Caenorhabditis elegans
頁次 : 1 / 2
Copyright © 2008 All Rights Reserved
